Annual Report 2024

Department of Hematopoietic Stem Cell Transplantation

Takahiro Fukuda, Sung-Won Kim, Ayumu Ito, Mizuki Watanabe, Wataru Takeda, Tsuneaki Hirakawa, Yu Akahoshi, Asako Usui

Introduction

 We provide care for patients undergoing allogeneic or autologous hematopoietic stem cell transplantation (HSCT). The transplant units comprise 26 beds on Ward 12B and 3 beds on Ward 11A. All rooms are supplied by a central high-efficiency particulate air (HEPA) filtration system.

The Team and What We Do

 Eight staff physicians (Drs. Kim, Ito, Watanabe, Takeda, Hirakawa, Akahoshi, Usui, and Fukuda) participate in the transplant program. Pediatric HSCT is managed in collaboration with the Department of Pediatric Oncology. In fiscal year 2024 (FY2024), a total of 78 HSCT procedures were performed, including 65 allogeneic transplants. Our department is characterized by a high volume of unrelated peripheral blood stem cell transplantation (U-PBSCT; n=25) and HLA-haploidentical related transplantation (n=18). Allogeneic transplantation for lymphoma and adult T-cell leukemia/lymphoma (ATL) accounted for about half of all indications. The number of each HSCT type performed in FY2024 is shown in Table 1.

Table 1. Number of each type of HSCT

 We hold a weekly multidisciplinary conference on Mondays with the Departments of Hematology and Pediatric Oncology, where we review approximately 30 inpatients and prospective candidates for HSCT. The transplant unit is staffed by 24 nurses trained in oncology and specialized supportive care for HSCT patients. The nursing team has taken leadership to improve care for graft-versus-host disease (GVHD) and to provide long-term follow-up (LTFU) care and education to patients and their family members. In FY2024, there were 350 billed LTFU visits, and 24 patients received outpatient rehabilitation as part of survivorship care. All HSCT inpatients are also reviewed in detail every Friday by the entire transplant team, including physicians, nurses, pharmacists, the nutrition support team, the rehabilitation team, the psychosocial support team, medical social workers, and hematopoietic cell transplant coordinators (HCTCs).

Research Activities / Clinical Trials

 Regarding the rare malignancy ATL, we have organized the national program of the Japan Agency for Medical Research and Development (AMED) since FY2014 and have conducted a post-transplant cyclophosphamide (PTCy)-based U-PBSCT study (Advanced Medical Care B) since FY2020. A nationwide registry for aggressive ATL commenced in August 2021, and a biorepository in March 2022; by the end of FY2024, 730 clinical cases and 394 biological specimens had been registered. We also conducted 12 secondary studies utilizing the registry dataset.

 To strengthen the foundations for late-effect management, we focused on LTFU, return to work, revaccination, and secondary malignancies among long-term survivors. The proportion of facilities able to bill the LTFU clinic fee increased from 63% (2018 survey) to 82%, and the outcomes were reported at domestic and international meetings in February 2025.

 Within the Ministry of Health, Labour and Welfare (MHLW) research program on infectious diseases and immunization, we prepared an implementation-oriented proposal on revaccination with high-priority public vaccines for allogeneic transplant recipients, balancing feasibility and safety.

 In parallel, an MHLW program to strengthen bone marrow donor infrastructure advanced: we evaluated an educational video promoting donation-leave policies, conducted a large-scale survey on long-term donor motivation and family support, and piloted an integrated web enrollment flow linked with buccal-swab return.

 Across FY2024, 47 English-language papers were accepted for publication from our group.

Education

 We trained five residents to develop their clinical skills in the management of HSCT patients in FY2024.

Future Prospects

 Our goal is to develop optimal strategies for HSCT to achieve a cure for patients with hematologic malignancies.

List of papers published in 2024

Journal

1. Yoshimitsu M, Tanaka T, Nakano N, Kato K, Muranushi H, Tokunaga M, Ito A, Ishikawa J, Eto T, Morishima S, Kawakita T, Itonaga H, Uchida N, Tanaka M, Akizuki K, Ishitsuka K, Ohigashi H, Ota S, Ando T, Kanda Y, Fukuda T, Atsuta Y, Fuji S. Comparative outcomes of various transplantation platforms, highlighting haploidentical transplants with post-transplantation cyclophosphamide for adult T-cell leukaemia/lymphoma. British journal of haematology, 206:235-249, 2025

2. Tamaki M, Kawamura S, Takano K, Nakamae H, Doki N, Ohigashi H, Maruyama Y, Ota S, Hiramoto N, Eto T, Yoshihara S, Matsuoka KI, Masuko M, Onizuka M, Kanda Y, Fukuda T, Atsuta Y, Yanagisawa R, Yakushijin K, Nakasone H. Female-to-male allogeneic transplantation affects outcomes differently according to the type of haplo-transplantation. Cytotherapy, 27:213-221, 2025

3. Okada Y, Tachi N, Shimazu Y, Murata M, Nishiwaki S, Onishi Y, Jinguji A, Uchida N, Tanaka M, Hasegawa Y, Ito A, Kako S, Nishida T, Onodera K, Sawa M, Nakamae H, Toyosaki M, Kanda Y, Onizuka M, Fukuda T, Ohbiki M, Atsuta Y, Arai Y, Tachibana T. Comparing de novo chronic myeloid leukemia in blastic phase with Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Cancer, 131:e35627, 2025

4. Marumo A, Nagata Y, Fujioka M, Kurosawa S, Najima Y, Sakaida E, Doki N, Fukushima K, Ota S, Shono K, Ito A, Uchida N, Nishida T, Sawa M, Tsunemine H, Matsuoka KI, Makoto O, Kanda Y, Fukuda T, Atsuta Y, Itonaga H. Outcome of donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation in relapsed myelodysplastic syndrome. Cytotherapy, 27:222-228, 2025

5. Miyao K, Murata M, Nishida T, Ozawa Y, Uchida N, Fukuda T, Doki N, Eto T, Kawakita T, Mori Y, Takada S, Ohigashi H, Tanaka M, Kanda Y, Matsuoka KI, Ishimaru F, Atsuta Y, Kanda J, Terakura S. Association between early anti-cytomegalovirus therapy and the incidence of chronic graft-versus-host disease. International journal of hematology, 121:110-125, 2025

6. Konuma T, Kameda K, Morita K, Kondo T, Kimura F, Nakasone H, Ouchi F, Uchida N, Tanaka M, Nishida T, Fukuda T, Hasegawa Y, Sakata-Yanagimoto M, Onizuka M, Sawa M, Ota S, Asada N, Fujiwara SI, Yoshihara S, Ishimaru F, Yoshimitsu M, Kanda Y, Ohbiki M, Atsuta Y, Yanada M. Different impacts of granulocyte colony-stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type. American journal of hematology, 100:66-77, 2025

7. Harada K, Kanda J, Hirayama M, Wada F, Uchida N, Tanaka M, Nakamae H, Tokunaga M, Ishiwata K, Onizuka M, Hasegawa Y, Fukuda T, Eto T, Kurita N, Kawakita T, Jinguji A, Ishimaru F, Atsuta Y, Nakasone H. Comparison of Nonrelapse Mortality After Haploidentical Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide Versus Single Umbilical Cord Blood Transplantation in Hematologic Disease. Transplantation and cellular therapy, 31:103.e1-103.e13, 2025

8. Shimomura Y, Kitamura T, Yanada M, Mizuno S, Kondo T, Yoshihara S, Tanaka M, Inai K, Katayama Y, Onizuka M, Fukuda T, Nakamae H, Kurokawa M, Yano S, Nara M, Masuko M, Miyakoshi S, Eto T, Yoshimitsu M, Ishimaru F, Kanda J, Atsuta Y, Konuma T. Allogeneic hematopoietic stem cell transplantation using reduced intensity conditioning regimen for patients with acute myeloid leukemia not in complete remission. Cytotherapy, 27:316-323, 2025

9. Mitsuyuki S, Shimomura Y, Mizumaki H, Yanada M, Mizuno S, Uchida N, Doki N, Ito A, Tanaka M, Nishida T, Katayama Y, Yoshihara S, Eto T, Takada S, Ota S, Toyosaki M, Hasegawa Y, Nakamae H, Kawamura K, Onizuka M, Fukuda T, Ohbiki M, Atsuta Y, Konuma T. Allogeneic hematopoietic stem cell transplantation in adult acute myeloid leukemia with t(16;21)(p11;q22)/FUS::ERG. Leukemia, 39:495-498, 2025

10. Jimbo K, Ishigaki T, Sakashita M, Andoh S, Ichimura H, Ito A, Yokoyama K, Sato A, Fukuda T, Uchimaru K, Nannya Y. Prognosis of aggressive adult T-cell leukemia/lymphoma with central nervous system infiltration and utility of CD7 versus CADM1 flowcytometric plots of cerebrospinal fluid. Annals of hematology, 104:635-640, 2025

11. Yamasaki S, Yanada M, Araie H, Fukuda T, Kanda Y, Tashiro H, Uchida N, Ozeki K, Ota S, Onishi Y, Doki N, Oyake T, Takada S, Sakurai M, Kondo Y, Nakamae H, Kawakita T, Onizuka M, Atsuta Y, Konuma T. Comparative analysis of allogeneic hematopoietic cell transplantation in patients with therapy-related and de novo acute promyelocytic leukemia A retrospective study. Scientific reports, 15:10967, 2025

12. Kim H, Mizuno K, Masuda K, Sakurai M, Ara T, Naito K, Uehara Y, Yamamoto G, Osada M, Machida S, Horio T, Fukushima K, Mori Y, Ichinohe T, Fukuda T, Atsuta Y, Kataoka K. A Nationwide Retrospective Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Adult Hemophagocytic Lymphohistiocytosis. Transplantation and cellular therapy, 30:419.e1-419.e12, 2024

13. Nishiwaki S, Sugiura I, Fujisawa S, Hatta Y, Atsuta Y, Doki N, Kurahashi S, Ueda Y, Dobashi N, Maeda T, Matsumura I, Tanaka M, Kako S, Ichinohe T, Fukuda T, Ohtake S, Ishikawa Y, Miyazaki Y, Kiyoi H. Utility of allogeneic stem cell transplantation for adult Ph+ALL with complete molecular remission. American journal of hematology, 99:806-815, 2024

14. Yanada M, Yano S, Kuwatsuka Y, Kawamura K, Fukuda T, Ichinohe T, Hashii Y, Goto H, Kato K, Ishimaru F, Sato A, Onizuka M, Matsuo K, Ito Y, Yanagisawa A, Ohbiki M, Tabuchi K, Atsuta Y, Kanda J, Konuma T. The effect of center experience on allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia. Bone marrow transplantation, 59:541-549, 2024

15. Akahoshi Y, Spyrou N, Hoepting M, Aguayo-Hiraldo P, Ayuk F, Chanswangphuwana C, Choe HK, Eder M, Etra AM, Grupp SA, Hexner EO, Hogan WJ, Kitko CL, Kraus S, Al Malki MM, Merli P, Qayed M, Reshef R, Schechter T, Ullrich E, Vasova I, Wölfl M, Zeiser R, Baez J, Beheshti R, Eng G, Gleich S, Kasikis S, Katsivelos N, Kowalyk S, Morales G, Young R, DeFilipp Z, Ferrara JLM, Levine JE, Nakamura R. Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis. Blood advances, 8:2047-2057, 2024

16. Kurosawa S, Shimomura Y, Itonaga H, Katayama Y, Onizuka M, Tanaka M, Kobayashi H, Ozawa Y, Sawa M, Kanda J, Doki N, Fujisawa S, Uchida N, Fukuda T, Atsuta Y, Ishiyama K. Comparison of Melphalan Dose in Patients with Myelodysplastic Syndrome Undergoing Allogeneic Transplantation with Reduced-Intensity Conditioning. Transplantation and cellular therapy, 30:510.e1-510.e10, 2024

17. Kuwatsuka Y, Kasajima R, Yamaguchi R, Uchida N, Konuma T, Tanaka M, Shingai N, Miyakoshi S, Kozai Y, Uehara Y, Eto T, Toyosaki M, Nishida T, Ishimaru F, Kato K, Fukuda T, Imoto S, Atsuta Y, Takahashi S. Machine Learning Prediction Model for Neutrophil Recovery after Unrelated Cord Blood Transplantation. Transplantation and cellular therapy, 30:444.e1-444.e11, 2024

18. Yamamoto R, Hiramoto N, Fujimoto A, Yamazaki H, Mori T, Uchida N, Doki N, Kato J, Nishikubo M, Kako S, Nishida T, Ota S, Onizuka M, Eto T, Onodera K, Ikegame K, Matsuoka KI, Kanda Y, Fukuda T, Atsuta Y, Onishi Y. Impact of antithymocyte globulin usage and risk stratification for posttransplant lymphoproliferative disorders in aplastic anemia patients after allogeneic hematopoietic cell transplantation. Bone marrow transplantation, 59:688-691, 2024

19. Nakaya Y, Nakamae H, Nishikubo M, Kondo E, Fukuda T, Hiramoto N, Mori Y, Nagafuji K, Eto T, Onishi Y, Uchida N, Ishikawa J, Matsuoka KI, Yui S, Takase K, Kawakita T, Kanda J, Ichinohe T, Atsuta Y, Kako S. Peripheral blood stem cell transplantation using HLA-haploidentical donor with post-transplant cyclophosphamide versus HLA-matched sibling donor for lymphoma. Bone marrow transplantation, 59:630-636, 2024

20. Kuriyama K, Fuji S, Ito A, Doki N, Katayama Y, Ohigashi H, Nishida T, Serizawa K, Eto T, Uchida N, Kanda Y, Tanaka M, Matsuoka KI, Nakazawa H, Kanda J, Fukuda T, Atsuta Y, Ogata M. Impact of Different Fludarabine Doses in the Fludarabine-Based Conditioning Regimen for Unrelated Bone Marrow Transplantation. Transplantation and cellular therapy, 30:514.e1-514.e13, 2024

21. Ogata M, Oshima K, Takano K, Kawano R, Ueda Y, Imamura T, Nakamura Y, Okada T, Toubai T, Ueki T, Uoshima N, Ishida H, Shinohara A, Seo S, Fukuda T, Inagaki M. Effects of human herpesvirus 6B reactivation on cognitive function in cord blood transplant recipients: a prospective multicenter study. International journal of hematology, 119:432-441, 2024

22. Konuma T, Uchida N, Takeda W, Doki N, Yoshihara S, Nishida T, Kuriyama T, Tanaka M, Ohigashi H, Nakamae H, Katayama Y, Ota S, Hashii Y, Ishimaru F, Fukuda T, Ohbiki M, Atsuta Y. RhD mismatch does not affect haematopoietic recovery, graft-versus-host disease and survival in allogeneic haematopoietic cell transplantation: A Japanese registry-based study. Vox sanguinis, 119:612-618, 2024

23. Shibata S, Arai Y, Kondo T, Mizuno S, Yamasaki S, Akasaka T, Doki N, Ota S, Maruyama Y, Matsuoka KI, Nagafuji K, Eto T, Tanaka T, Ohigashi H, Nakamae H, Onizuka M, Fukuda T, Atsuta Y, Yanada M. Prognostic factors in haploidentical transplantation with post-transplant cyclophosphamide for acute myeloid leukemia. Cytotherapy, 26:592-598, 2024

24. Akahoshi Y. Selection of statistical tests considering competing risks: the importance of understanding the assumptions in each test. Blood advances, 8:2571-2572, 2024

25. Konuma T, Miyao K, Nakasone H, Ouchi F, Fukuda T, Tanaka M, Ozawa Y, Ota S, Kawakita T, Uchida N, Sawa M, Katayama Y, Hiramoto N, Eto T, Ichinohe T, Atsuta Y, Kanda J. Allogeneic transplantation of bone marrow versus peripheral blood stem cells from HLA-identical sibling donors for hematological malignancies in 6064 adults from 2003 to 2020: different impacts on survival according to time period. Cytotherapy, 26:910-920, 2024

26. Konishi T, Matsuda K, Itonaga H, Doki N, Nishida T, Matsuoka KI, Ikeda T, Kanda Y, Fukuda T, Kanda J, Nakamae H, Imada K, Ueda Y, Ichinohe T, Atsuta Y, Ishiyama K. Impact of Early Cytomegalovirus Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation on Relapse in Patients With Myelodysplastic Syndrome: A Nationwide Retrospective Study From Adult Myelodysplastic Syndrome Working Group of the JSTCT. Transplantation and cellular therapy, 30:685.e1-685.e12, 2024

27. Itonaga H, Miyazaki Y, Fujioka M, Aoki J, Doki N, Nishida T, Fukuda T, Uchida N, Ueda Y, Uehara Y, Katayama Y, Ota S, Kawakita T, Kato J, Matsuoka KI, Eto T, Onizuka M, Ichinohe T, Atsuta Y, Ishiyama K. Prognostic impact of the conditioning intensity on outcomes after allogeneic transplantation for MDS with low blasts: a nationwide retrospective study by the adult MDS working group of the Japan Society for Transplantation and Cellular Therapy. Bone marrow transplantation, 59:1107-1117, 2024

28. Nakamura Y, Zaimoku Y, Yamaguchi H, Yamazaki H, Kanaya M, Uchida N, Doki N, Sakurai M, Hiramoto N, Kako S, Onizuka M, Onodera K, Maruyama Y, Ohigashi H, Nishida T, Yoshihara S, Matsuoka KI, Eto T, Kanda Y, Fukuda T, Atsuta Y, Onishi Y. Significance of absolute neutrophil count before allogeneic hematopoietic stem cell transplantation in adult patients with aplastic anemia. Annals of hematology, 103:3121-3133, 2024

29. Terao T, Matsuoka KI, Fuji S, Kawamura S, Toya T, Doki N, Uchida N, Tanaka M, Fukuda T, Sawa M, Ishikawa J, Nishida T, Ohigashi H, Maruyama Y, Fujiwara SI, Kanda Y, Ota S, Ishimaru F, Atsuta Y, Kanda J, Ogata M, Yakushijin K, Nakasone H. Association between human herpesvirus-6 encephalitis and antiviral prophylaxis after allogeneic hematopoietic stem cell transplantation in the letermovir era. Bone marrow transplantation, 59:1224-1231, 2024

30. Kurosawa S, Fukuda T, Ichinohe T, Hashii Y, Kanda J, Goto H, Kato K, Yoshimitsu M, Ishimaru F, Sato A, Onizuka M, Matsuo K, Ito Y, Yanagisawa A, Ohbiki M, Tabuch K, Atsuta Y, Arai Y. Center effect on allogeneic hematopoietic stem cell transplantation outcomes for B-cell acute lymphoblastic leukemia. Cytotherapy, 26:1185-1192, 2024

31. Jimbo K, Kawamata T, Inamoto Y, Ito A, Yokoyama K, Sato A, Fukuda T, Uchimaru K, Nannya Y. Flow cytometric profiles with CD7 and CADM1 in CD4+ T cells are promising indicators for prognosis of aggressive ATL. Blood advances, 8:3760-3770, 2024

32. Kuwatsuka Y, Ito H, Tabuchi K, Konuma T, Uchida N, Inamoto Y, Inai K, Nishida T, Ikegame K, Eto T, Katayama Y, Kataoka K, Tanaka M, Takahashi S, Fukuda T, Ichinohe T, Kimura F, Kanda J, Atsuta Y, Matsuo K. Trends in allogeneic hematopoietic cell transplantation survival using population-based descriptive epidemiology method: analysis of national transplant registry data. Bone marrow transplantation, 59:1295-1301, 2024

33. Kawamura S, Tamaki M, Konuma T, Onizuka M, Sakaida E, Hayashi H, Doki N, Nishida T, Sawa M, Ohigashi H, Fukuda T, Ishikawa J, Matsuoka KI, Kawakita T, Tanaka M, Ishimaru F, Ichinohe T, Atsuta Y, Kanda Y, Yakushijin K, Kanda J, Nakasone H. Superiority of BM over PBSC for recipients with pre-transplant lung dysfunction in HLA-matched allogeneic HCT. Cytotherapy, 26:1353-1361, 2024

34. Kanda J, Mitsuyoshi T, Sakurai M, Nishimori H, Murata M, Uchida N, Doki N, Inamoto Y, Nishida T, Tanaka M, Katayama Y, Eto T, Matsuoka KI, Yoshihara S, Sawa M, Kawakita T, Jun G, Kurata M, Ichinohe T, Fukuda T, Teshima T, Atsuta Y, Terakura S. Real-World Outcomes of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation in Japan: Retrospective Analysis of the Transplant Registry Unified Management Program Registry. Transplantation and cellular therapy, 30:907.e1-907.e16, 2024

35. Akahoshi Y, Spyrou N, Weber D, Aguayo-Hiraldo P, Ayuk F, Chanswangphuwana C, Choe HK, Eder M, Etra AM, Grupp SA, Hexner EO, Hogan WJ, Kitko CL, Kraus S, Al Malki MM, Merli P, Qayed M, Reshef R, Schechter T, Ullrich E, Vasova I, Wölfl M, Zeiser R, Baez J, Beheshti R, Eng G, Gleich S, Katsivelos N, Kowalyk S, Morales G, Young R, Chen YB, Nakamura R, Levine JE, Ferrara JLM. Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD. Blood, 144:1010-1021, 2024

36. Ido K, Nakamae H, Hattori N, Kanaya M, Morita K, Hino M, Ohigashi H, Fukuda T, Eto T, Nagafuji K, Hiramoto N, Maruyama Y, Ota S, Matsuoka KI, Ando T, Akasaka T, Mori Y, Kamimura T, Kawakita T, Kawamura K, Kanda J, Onizuka M, Atsuta Y, Murata M. Effect of peptide-binding motif on survival of HLA-haploidentical transplantation with post-transplant cyclophosphamide. British journal of haematology, 205:1077-1096, 2024

37. Tamaki M, Akahoshi Y, Inamoto Y, Morita K, Uchida N, Doki N, Tanaka M, Nishida T, Ohigashi H, Nakamae H, Onizuka M, Katayama Y, Matsuoka KI, Sawa M, Ishimaru F, Kanda Y, Fukuda T, Atsuta Y, Terakura S, Kanda J. Associations between acute and chronic graft-versus-host disease. Blood advances, 8:4250-4261, 2024

38. Kamijo K, Shimomura Y, Kim SW, Ohigashi H, Ishikawa J, Eto T, Hiramoto N, Mizuno I, Iida S, Ueda Y, Matsuoka KI, Yakushijin K, Mori Y, Onizuka M, Fukuda T, Atsuta Y, Kako S. Reduced-intensity conditioning with fludarabine/busulfan versus fludarabine/low-dose melphalan in patients with non-Hodgkin lymphoma undergoing allogeneic haematopoietic stem cell transplantation. British journal of haematology, 205:1097-1107, 2024

39. Fuji S, Nakamae H, Sugita J, Najima Y, Konishi T, Tanaka T, Nakashima Y, Nishimoto M, Okamura H, Nakayama K, Ito A, Yoshimitsu M, Hino M, Fukuda T, Atsuta Y, Yakushijin K. Lower-dose post-transplant cyclophosphamide in haploidentical hematopoietic cell transplantation. Bone marrow transplantation, 59:1628-1630, 2024

40. Rios CAO, Qayed M, Etra AM, Reshef R, Newcomb R, Yuhasz N, Hexner EO, Aguayo-Hiraldo P, Merli P, Hogan WJ, Weber D, Kitko CL, Ayuk F, Eder M, Grupp SA, Kraus S, Sandhu K, Ullrich E, Vasova I, Wölfl M, Baez J, Beheshti R, Eng G, Gleich S, Katsivelos N, Kowalyk S, Louloudis IE, Morales G, Spyrou N, Young R, Nakamura R, Levine JE, Ferrara JLM, Akahoshi Y. Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients. Transplantation and cellular therapy, 30:1061.e1-1061.e10, 2024

41. Nishikubo M, Shimomura Y, Nakaya Y, Shinohara A, Uchida N, Takayama N, Kobayashi H, Uehara Y, Ishikawa J, Ishiwata K, Hiramoto N, Nakazawa H, Kataoka K, Kanda J, Nagafuji K, Kozai Y, Matsuhashi Y, Ishimaru F, Kim SW, Fukuda T, Kanda Y, Atsuta Y, Kondo E, Kako S. Haploidentical transplantation with post-transplant cyclophosphamide versus single cord blood transplantation in adults with relapsed/refractory non-Hodgkin lymphoma. Bone marrow transplantation, 59:1735-1743, 2024

42. Katagiri T, Takahashi R, Zaimoku Y, Hosokawa K, Ogawa S, Takahashi Y, Miyamura T, Onishi Y, Koike T, Nishida T, Uchida N, Doki N, Tanaka M, Eto T, Itagaki M, Sawa M, Fukuda T, Onizuka M, Atsuta Y, Nakao S. Frequent loss of HLA-B*40:02 from leucocytes in male patients with hepatitis-associated aplastic anaemia. British journal of haematology, 205:2084-2088, 2024

43. Shimomura Y, Kitamura T, Sugita J, Terao T, Satake A, Hirakawa T, Uchida N, Shimabukuro M, Tanaka M, Eto T, Hiramoto N, Kataoka K, Nakamae H, Takase K, Kawakita T, Arai Y, Takeda W, Ishimaru F, Fukuda T, Atsuta Y, Nakasone H, Kanda J. Impact of donor type on the outcomes of acute graft versus host disease to systemic corticosteroid therapy. Bone marrow transplantation, 59:1763-1772, 2024

44. Itonaga H, Fukushima T, Kato K, Nakano N, Kato T, Tanaka T, Eto T, Mori Y, Kawakita T, Uchida N, Fujioka M, Nakamae H, Ogata M, Morishima S, Fukuda T, Kanda Y, Atsuta Y, Fuji S, Yoshimitsu M. Allogeneic transplantation for adult T-cell leukemia/lymphoma in adolescent and young adults and young patients: A nationwide retrospective study by the ATL working group of the Japan society for transplantation and cellular therapy. Hematological oncology, 42:e3315, 2024

45. Moriguchi M, Nakamae H, Nishimoto M, Sugita J, Yanada M, Toubai T, Hasegawa Y, Hino M, Nishida T, Kurita N, Sawa M, Fukuda T, Jinguji A, Ota S, Matsuoka KI, Eto T, Hiramoto N, Ando T, Kawamura K, Kanda Y, Atsuta Y, Ohbiki M, Nakasone H, Konuma T. Comparison of HLA-haploidentical donors with post-transplant cyclophosphamide versus HLA-matched unrelated donors in peripheral blood stem cell transplantation for acute myeloid leukaemia. British journal of haematology, 205:2376-2386, 2024

46. Mizuno S, Hosoi H, Takami A, Kawata T, Doki N, Takeda W, Tanaka M, Nishida T, Uchida N, Hasegawa Y, Sawa M, Ota S, Onizuka M, Nakamae H, Asada N, Fukuda T, Yoshimitsu M, Kanda Y, Ohbiki M, Atsuta Y, Konuma T, Yanada M. Reappraising the prognostic relevance of cytogenetic risk in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Annals of hematology, 103:5903-5913, 2024

47. Jo T, Inoue K, Ueda T, Iwasaki M, Akahoshi Y, Nishiwaki S, Hatsusawa H, Nishida T, Uchida N, Ito A, Tanaka M, Takada S, Kawakita T, Ota S, Katayama Y, Takahashi S, Onizuka M, Hasegawa Y, Kataoka K, Kanda Y, Fukuda T, Tabuchi K, Atsuta Y, Arai Y. Machine learning evaluation of intensified conditioning on haematopoietic stem cell transplantation in adult acute lymphoblastic leukemia patients. Communications medicine, 4:247, 2024